SELLAS Life Sciences Group, Inc. (SLS)
NasdaqCM · USD · Healthcare · Biotechnology
$12.17 (+7.32%) as of
Key statistics
- Market cap
- 2.46B
- Forward P/E
- -121.70
- EPS (TTM)
- -0.21
- Dividend yield
- 0.00%
- 52-week range
- 1.39 – 15.88
- Beta
- 2.57
- Profit margin
- 0.00%
- Analyst target
- $32.50
- Volume
- 6.18M
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, NY, United States
- Employees
- 13
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.